Woodcock Says Opioid Overprescribing Still An Issue, Defends FDA Actions

By Beth Wang / November 24, 2021 at 10:21 AM
Acting FDA chief Janet Woodcock defended FDA’s efforts to respond to the opioid epidemic, while also saying opioid overprescribing is still a problem that requires a change in prescriber behavior. But former FDA official Josh Sharfstein said there’s more FDA could do to respond to the crisis, including by making opioid use disorder treatments, like methadone and buprenorphine, more accessible, and increasing transparency around its opioid risk mitigation plans. Woodcock and Sharfstein made their comments during separate pre-recorded interviews posted...

Not a subscriber? Sign up for 30 days free access to exclusive, detailed reporting on drug pricing reforms, Medicaid policy, FDA news and much more.